当前位置: 首页 > 期刊 > 《上海医药》 > 2019年第11期
编号:13383861
蛋白酶体抑制剂治疗浆细胞疾病的研究进展(7)
http://www.100md.com 2019年4月15日 《上海医药》 2019年第11期
     [34] Castillo JJ, Kastritis E, Treon SP. Waldenstr?m macroglobulinemia: lessons learned from basic and clinical research[J]. Hematol Oncol Clin North Am, 2018, 32(5): xiii-xiv.

    [35] Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstr?m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180[J]. J Clin Oncol, 2009, 27(23): 3830-3835.

    [36] Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr?m macroglobulinemia [J]. Am J Hematol, 2010, 85(9): 670-674.

    [37] Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN) [J]. Blood, 2013, 122(19): 3276-3282.

    [38] Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr?m’s macroglobulinemia [J]. Blood, 2014, 124(4): 503-510., http://www.100md.com(戴昕 陈彤)
上一页1 2 3 4 5 6 7